{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T12:08:59Z","timestamp":1771416539829,"version":"3.50.1"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:00:00Z","timestamp":1762560000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100012331","name":"LEO Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,18]]},"abstract":"<jats:p>Paradoxical reactions following treatment with biologics are well-documented adverse effects. The risks of paradoxical plaque and pustular psoriasis among patients with various other immune-mediated inflammatory diseases following treatment with tumour necrosis factor \u03b1 inhibitors (TNFi) have been studied. Although case reports describe the emergence of pustular psoriasis in patients treated with all class of biologics for plaque psoriasis, population-level studies assessing risks between biologics are needed.<\/jats:p>","DOI":"10.1093\/bjd\/ljaf448","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:02:34Z","timestamp":1762520554000},"page":"577-579","source":"Crossref","is-referenced-by-count":0,"title":["Pustular psoriasis following treatment with biologics among patients with plaque psoriasis: a nationwide cohort study"],"prefix":"10.1093","volume":"194","author":[{"given":"Nikolai","family":"Loft","sequence":"first","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital \u2013 Herlev and Gentofte ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"Zachariae","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital \u2013 Herlev and Gentofte ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diljit","family":"Kaur-Knudsen","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital \u2013 Herlev and Gentofte ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4011-8308","authenticated-orcid":false,"given":"Christopher G","family":"Bunick","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, Yale University , New Haven, CT ,","place":["USA"]},{"name":"Program in Translational Biomedicine, Yale School of Medicine, Yale University , New Haven, CT ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Gilliet","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Lausanne University Hospital CHUV, University of Lausanne , Lausanne ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4784-9680","authenticated-orcid":false,"given":"Lone","family":"Skov","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy, Copenhagen University Hospital \u2013 Herlev and Gentofte ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, University of Copenhagen ,","place":["Denmark"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,8]]},"reference":[{"key":"2026021806322126100_ljaf448-B1","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1001\/jamadermatol.2022.2360","article-title":"Absolute and relative risk of new-onset psoriasis associated with tumor necrosis factor-\u03b1 inhibitor treatment in patients with immune-mediated inflammatory diseases: a Danish Nationwide cohort study","volume":"158","author":"Thein","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2026021806322126100_ljaf448-B2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/1756-185X.14661","article-title":"Tumor necrosis factor-\u03b1 inhibitor-associated psoriasis: facts and hypotheses","volume":"26","author":"Luo","year":"2023","journal-title":"Int J Rheum Dis"},{"key":"2026021806322126100_ljaf448-B3","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamadermatol.2024.1677","article-title":"Clinical characteristics associated with response to biologics in the treatment of psoriasis: a meta-analysis","volume":"160","author":"Hjort","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2026021806322126100_ljaf448-B4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1684\/ejd.2020.3702","article-title":"Paradoxical palmoplantar pustulosis induced by secukinumab and brodalumab: a report of three cases","volume":"30","author":"M\u00f6ssner","year":"2020","journal-title":"Eur J Dermatol"},{"key":"2026021806322126100_ljaf448-B5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s13555-021-00672-z","article-title":"Adalimumab biosimilar-induced severe paradoxical palmoplantar pustulosis in a patient with psoriasis and psoriatic arthritis successfully treated with ixekizumab","volume":"12","author":"Gkalpakiotis","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026021806322126100_ljaf448-B6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2021.0221","article-title":"Outcomes following a mandatory nonmedical switch from adalimumab originator to adalimumab biosimilars in patients with psoriasis","volume":"157","author":"Loft","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026021806322126100_ljaf448-B7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41467-017-02466-4","article-title":"TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis","volume":"9","author":"Conrad","year":"2018","journal-title":"Nature Comm"},{"key":"2026021806322126100_ljaf448-B8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00281-018-0712-y","article-title":"Female predisposition to TLR7-driven autoimmunity: gene dosage and the escape from X chromosome inactivation","volume":"41","author":"Souyris","year":"2019","journal-title":"Semin Immunopathol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf448\/65246093\/ljaf448.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/3\/577\/65246093\/ljaf448.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/3\/577\/65246093\/ljaf448.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T11:32:30Z","timestamp":1771414350000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/3\/577\/8317131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,8]]},"references-count":8,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,8]]},"published-print":{"date-parts":[[2026,2,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf448","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,11,8]]}}}